Home
About
Overview
Sharing Data
ORCID
Help
History (1)
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer. bioRxiv. 2024 May 23.
View in:
PubMed
authors with profiles
Tong-Chuan He